CN103748087A - 吲唑和吡咯并吡啶衍生物和其药学用途 - Google Patents

吲唑和吡咯并吡啶衍生物和其药学用途 Download PDF

Info

Publication number
CN103748087A
CN103748087A CN201280025823.9A CN201280025823A CN103748087A CN 103748087 A CN103748087 A CN 103748087A CN 201280025823 A CN201280025823 A CN 201280025823A CN 103748087 A CN103748087 A CN 103748087A
Authority
CN
China
Prior art keywords
optional
replacing
indazole
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280025823.9A
Other languages
English (en)
Chinese (zh)
Inventor
水野和弘
池田淳哉
中村高典
岩田昌门
大高广道
后藤奈奈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CN103748087A publication Critical patent/CN103748087A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280025823.9A 2011-06-07 2012-06-06 吲唑和吡咯并吡啶衍生物和其药学用途 Pending CN103748087A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-127688 2011-06-07
JP2011127688 2011-06-07
PCT/JP2012/065052 WO2012169649A1 (en) 2011-06-07 2012-06-06 Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
CN103748087A true CN103748087A (zh) 2014-04-23

Family

ID=47296200

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280025823.9A Pending CN103748087A (zh) 2011-06-07 2012-06-06 吲唑和吡咯并吡啶衍生物和其药学用途

Country Status (12)

Country Link
US (1) US20140057895A1 (https=)
EP (1) EP2718283A4 (https=)
JP (1) JP2014510708A (https=)
KR (1) KR20140041519A (https=)
CN (1) CN103748087A (https=)
AU (1) AU2012267797A1 (https=)
BR (1) BR112013030939A2 (https=)
CA (1) CA2833507A1 (https=)
MX (1) MX2013014427A (https=)
RU (1) RU2013157374A (https=)
TW (1) TW201311674A (https=)
WO (1) WO2012169649A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110099898A (zh) * 2016-10-24 2019-08-06 优曼尼蒂治疗公司 化合物及其用途
CN115417772A (zh) * 2022-09-26 2022-12-02 无锡双启科技有限公司 一种3-硝基-4-氟苯甲醚的制备方法
WO2023179366A1 (zh) * 2022-03-25 2023-09-28 星希尔生物科技(上海)有限公司 一种噁二唑衍生物及其制备方法和用途
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
US12180221B2 (en) 2018-03-23 2024-12-31 Janssen Pharmaceutica Nv Compounds and uses thereof
US12268687B2 (en) 2019-11-13 2025-04-08 Janssen Pharmaceutica Nv Compounds and uses thereof
US12433880B2 (en) 2017-01-06 2025-10-07 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016028016A (ja) * 2012-12-12 2016-02-25 大日本住友製薬株式会社 オキサジアゾール誘導体とその医薬用途
CU24275B1 (es) 2013-02-22 2017-10-05 Pfizer Derivados de cicloalquilo pirrolo [2,3-d] pirimidina-4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
KR102140508B1 (ko) 2016-09-28 2020-08-03 경희대학교 산학협력단 헌팅턴병의 예방 또는 치료용 조성물
PL3759109T3 (pl) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Podstawione związki pirolizyny jako inhibitory replikacji hbv
US12590083B2 (en) * 2019-01-25 2026-03-31 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
CA3189027A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN115947690B (zh) * 2022-12-13 2025-04-08 安徽医科大学 一种吲唑分子砌块的制备方法及其在药物合成中的应用
WO2025045837A1 (en) 2023-08-31 2025-03-06 Syngenta Crop Protection Ag Pesticidally active indazole compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101080406A (zh) * 2004-12-22 2007-11-28 施万制药 吲唑－甲酰胺化合物
WO2008006793A1 (en) * 2006-07-14 2008-01-17 Glaxo Group Limited Indole compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7906532B2 (en) * 2005-07-22 2011-03-15 Pfizer Inc. Indazole derivatives
GB0901487D0 (en) * 2009-01-30 2009-03-11 Movetis N V Asthma Therapy
US9000175B2 (en) * 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
AP3307A (en) * 2011-09-19 2015-06-30 Suven Life Sciences Ltd Heteroaryl compounds as 5-HT4 receptor ligands

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101080406A (zh) * 2004-12-22 2007-11-28 施万制药 吲唑－甲酰胺化合物
WO2008006793A1 (en) * 2006-07-14 2008-01-17 Glaxo Group Limited Indole compounds
US20090298866A1 (en) * 2006-07-14 2009-12-03 Adrian Hall Indole Compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY: "RN1002158-87-3", 《STN》, 8 February 2008 (2008-02-08) *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110099898A (zh) * 2016-10-24 2019-08-06 优曼尼蒂治疗公司 化合物及其用途
CN110099898B (zh) * 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
US12433880B2 (en) 2017-01-06 2025-10-07 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US12275723B2 (en) 2017-10-24 2025-04-15 Janssen Pharmaceutica Nv Compounds and uses thereof
US12180221B2 (en) 2018-03-23 2024-12-31 Janssen Pharmaceutica Nv Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
US12268687B2 (en) 2019-11-13 2025-04-08 Janssen Pharmaceutica Nv Compounds and uses thereof
WO2023179366A1 (zh) * 2022-03-25 2023-09-28 星希尔生物科技(上海)有限公司 一种噁二唑衍生物及其制备方法和用途
CN115417772A (zh) * 2022-09-26 2022-12-02 无锡双启科技有限公司 一种3-硝基-4-氟苯甲醚的制备方法

Also Published As

Publication number Publication date
AU2012267797A1 (en) 2014-01-09
KR20140041519A (ko) 2014-04-04
EP2718283A1 (en) 2014-04-16
TW201311674A (zh) 2013-03-16
RU2013157374A (ru) 2015-07-20
BR112013030939A2 (pt) 2016-12-06
WO2012169649A1 (en) 2012-12-13
AU2012267797A2 (en) 2014-05-22
MX2013014427A (es) 2014-01-23
JP2014510708A (ja) 2014-05-01
CA2833507A1 (en) 2012-12-13
EP2718283A4 (en) 2014-10-29
US20140057895A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
CN103748087A (zh) 吲唑和吡咯并吡啶衍生物和其药学用途
CA3222144A1 (en) Substituted indole compounds and methods of use thereof
JP2013010719A (ja) ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
AU2015330141B2 (en) Spirodiamine derivatives as aldosterone synthase inhibitors
DK2861566T3 (en) NEW DIAZASPIROCYCLOALKANES AND AZASPIROCYCLOALKANES
DK2545045T3 (en) PIPERIDINE-4-YL-azetidine derivatives AS JAK1 INHIBITORS
TWI780511B (zh) Trpc 6抑制劑
JP5657518B2 (ja) 縮合複素環化合物
CN1802187B (zh) 趋化因子受体的苯并噁嗪基-酰胺基环戊基-杂环调节剂
JP2014133739A (ja) インダゾール誘導体またはピロロピリジン誘導体からなる医薬
WO2014092104A1 (ja) オキサジアゾール誘導体とその医薬用途
KR20170045749A (ko) Ｓｍｙｄ 억제제
JP2010524984A (ja) Ｐ２ｙ１２アンタゴニストとしてのキノリン−カルボキサミド誘導体
JP2013515033A (ja) オレキシン受容体アンタゴニストとしてのジアザ−スピロ［５．５］ウンデカン類
KR20170048563A (ko) 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도
WO2022152852A1 (en) Antagonists of mrgx2
JP7661533B2 (ja) Ｎｒｆ２活性化作用を有する含窒素複素環化合物
WO2024049977A1 (en) Substituted indole compounds and methods of use thereof
CA2903180C (en) 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
CN105189508A (zh) 作为janus激酶抑制剂的环烷基腈吡唑并吡啶酮
TW202309006A (zh) 作為ｓｉｇｍａ配體的新穎吡啶磺醯胺衍生物、其製備方法及用途，以及包含該吡啶－磺醯胺衍生物的醫藥組成物
CA2902848C (en) 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
KR20090040352A (ko) 유로텐신 ⅱ 수용체 길항제
TW202309017A (zh) 作為Ｓｉｇｍａ配體的１Ｈ－吡唑衍生物
WO1999028307A1 (en) Alicyclic acylated heterocyclic derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140423